Dataset Information

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

ABSTRACT: Inhibition of the lipid kinase PI3K? is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3K? isoform selective analogues with good pharmacokinetic properties. With compound 11, we illustrate that biochemical PI3K? inhibition translates into modulation of isoform-dependent immune cell function (human, rat, and mouse). After oral administration of compound 11 to rats, proximal PD markers are inhibited, and dose-dependent efficacy in a mechanistic plaque forming cell assay could be demonstrated.

SUBMITTER: Hoegenauer K

PROVIDER: S-EPMC4983741 | biostudies-other | 2016 Aug

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Hoegenauer Klemens K Soldermann Nicolas N Stauffer Frédéric F Furet Pascal P Graveleau Nadege N Smith Alexander B AB Hebach Christina C Hollingworth Gregory J GJ Lewis Ian I Gutmann Sascha S Rummel Gabriele G Knapp Mark M Wolf Romain M RM Blanz Joachim J Feifel Roland R Burkhart Christoph C Zécri Frédéric F

ACS medicinal chemistry letters 20160602 8

Inhibition of the lipid kinase PI3Kδ is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3Kδ isoform selective analogues with good pharmacokinetic properties. With compound 11, we illustrate that biochemical PI3Kδ inhibition translates into modulation of isoform-dependent immune cell function (human, rat, and mouse). After oral administration of co ...[more]

PMID: 27563400

Dataset Information

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Publications

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Similar Datasets

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
| S-EPMC5601375 | biostudies-literature

Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3K?) inhibitors.
| S-EPMC6009876 | biostudies-literature

Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
| S-EPMC5094563 | biostudies-literature

Synthesis and multifaceted pharmacological activity of novel quinazoline NHE-1 inhibitors.
| S-EPMC8692498 | biostudies-literature

Discovery and lead identification of quinazoline-based BRD4 inhibitors.
| S-EPMC7392372 | biostudies-literature

Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors.
| S-EPMC4394348 | biostudies-literature

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
| S-EPMC5980294 | biostudies-literature

Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors.
| S-EPMC6232652 | biostudies-literature

Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.
| S-EPMC3183329 | biostudies-literature

Identification of Novel PI3K? Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations.
| S-EPMC6928688 | biostudies-literature